Anteris Technologies Global Corp. Announces First IPO in the U.S.
Anteris Technologies Global Corp. ("ATGC") announced today that it has commenced the roadshow presentations for its proposed initial public offering ("Offering") of 14,800,000 shares of common stock ("Common Stock") in the United States. All Common Stock to be sold in the Offering will be offered by ATGC. Additionally, ATGC plans to grant underwriters a 30-day option to purchase up to 2,220,000 additional shares of Common Stock at the initial public offering price less underwriters' discounts and commissions. ATGC has filed an application to list the Common Stock on the Nasdaq Global Market under the symbol "AVR."
ATGC intends to use the net proceeds from the Offering, along with existing cash and cash equivalents, primarily to continue the development of the DurAVR® transcatheter heart valve ("DurAVR® THV") and prepare for patient enrollment in the randomized global pivotal study for the treatment of severe aortic stenosis. The remaining proceeds will be used for working capital and other general corporate purposes as may be determined from time to time, including the repayment of amounts owed under convertible debt instruments. TD Cowen, Barclays, and Cantor will serve as joint book-running managers for the proposed Offering, while Lake Street Capital Markets will act as lead manager.
Following the Offering, ATGC intends to list CHESS Depositary Interests ("CDIs") on the Australian Securities Exchange ("ASX") under the symbol "AVR," representing 1 CDI for each 1 share of Common Stock.
The proposed Offering will be made solely by means of a prospectus. Copies of the preliminary prospectus related to the Offering will be available when filed at the following addresses: TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, phone: (855) 495-9846 or email: TD.ECM_Prospectus@tdsecurities.com; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue Edgewood, NY 11717, phone: (888) 603-5847 or email: Barclaysprospectus@broadridge.com; or Cantor Fitzgerald & Co., 110 East 59th Street, 6th Floor, New York, NY 10022, phone: (212) 915-1800 or email: prospectus@cantor.com.
A registration statement on Form S-1 relating to the Common Stock has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any offer, solicitation, or sale of securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. As disclosed in the registration statement, underwriters may engage in stabilization activities or related transactions in connection with the Offering.
About ATGC
ATGC was established to reorganize the operations of Anteris Technologies Ltd, an Australian public company registered in Western Australia and listed on the ASX, with the ultimate parent company being a Delaware corporation.
About Anteris Technologies Ltd (AVR)
Anteris Technologies Ltd (AVR) is a structural heart company focused on designing, developing, and commercializing innovative medical devices. Established in Australia and with a significant presence in Minneapolis, USA (a MedTech hub), Anteris works scientifically with a team of experienced, multidisciplinary professionals committed to providing potentially transformative solutions for patients with structural heart disease.
Anteris's lead product, DurAVR®, is a transcatheter heart valve used to treat aortic stenosis. It is the first transcatheter aortic valve replacement utilizing a single-piece tissue made from a biomimetic material. This valve is uniquely designed to mimic the performance of a healthy human aortic valve.
DurAVR® THV is made using Anteris’s proprietary anti-calcification tissue technology, known as ADAPT® tissue, which has been clinically used for over 10 years and distributed in more than 55,000 patients worldwide.
The ComASUR® Delivery System is designed to enable the controlled placement and accurate positioning of the DurAVR® THV. The balloon-expandable delivery system is designed to provide precise alignment with the heart’s natural commissures for optimal valve positioning.
This article has been generated with the support of artificial intelligence, translated, and reviewed by an editor. For more information, please refer to our Terms and Conditions section.